domino pizza inc hold pt downgrad hold valuat believ posit price
inc hold strong execut breast implant miradri howev downgrad hold buy
coffe hold compani jva buy pt review triple-beat quarter increment sale growth boost
steep like follow analyst stephen anderson full summari
athersi inc buy pt expand collabor helio indic non-dilut capit
posit analyst jason mccarthi ph full summari
brainstorm cell inc bcli buy pt warrant extend runway al data evalu move
signific opportun exist acn rosacea analyst anthoni vendetti full summari
corpor event call maxim salesperson inform
genprex inc gnpx ndr nyc ceo rodney varner wed jun
dare bioscienc inc dare ndr nyc ceo sabrina johnson tue jun
capricor inc capr ndr nyc ceo linda marban cfo aj bergmann thur jun
opinion leader dinner event highlight genomics/gen edit challeng path forward host maxim
annual summer confer host vendetti chokshi jang abwn bhtg
cover ndr boston cfo golder wed jun
cover hq visit orlando ceo gene cfo cardena
annual summer confer host vendetti chokshi jang abwn bhtg
domino pizza inc cover hq meet ann arbor ceo ritch allison cfo jeff
annual silicon valley bu tour host chokshi tue juli
annual summer confer host vendetti chokshi jang abwn bhtg
alarm com hold inc cover chokshi ndr milwauke cfo steve valenzuela tue sep
bioscienc yten ndr nyc ceo oliv peopl vice-president plan corpor commun lynn
profir energi inc pfie cover jang ndr boston ceo brenton hatch cfo ryan oviatt tue juli
annual summer confer host vendetti chokshi jang abwn bhtg
downgrad hold valuat believ posit
price share maintain price target
downgrad share hold buy
share price surpass price target yesterday
although argu dpz comp perform market share gain
 acceler unit develop world-wide mostli favor cost
outlook warrant premium multipl believ posit
price share
share risen year-to-d vs industri averag year-
to-dat trade near peak cyclic multipl forward price-to-earnings nearli
turn closest peer
downgrad share share price surpass price target
yesterday highlight benefit follow factor
believ continu next quarter
above-p same-restaur sale past month gain
market share pizza quick-servic categori grown
pace period includ result fast-grow privately-held
casual pizza chain comparison estim period pizza
hut own yumnr lost share papa john
pzzanr lost share
new unit expans world-wide new unit growth
world-wide outpac growth papa john pizza hut
 domest franchise ad new unit strongest pace sinc
earli outsid expect new unit growth skew toward high
end guidanc particularli local brand convert domino
benign food cost given corn wheat price still near multi-year low stabl
dairi cost recent retreat pork cost expect food cost inflat
less project manag investor day januari
potenti cost save digit compani
earn confer call april outgo ceo patrick doyl announc
plan push toward digit incom order anticip
full launch follow test believ initi help
reduc labor hour thu mitig impact rise wage
refinanc estim recent complet million refinanc
modestli dilut ep accret ep
detail april compani report
nevertheless believ strong year-to-d perform
share price posit fairli valu dpz forward
price-to-earnings multipl well closest peer forward
price-to-earnings multipl base consensu ep estim acknowledg
wide gap valuat multipl reflect manag abil execut well
well recent stumbl howev contend near peak
cyclic valuat multipl potenti upsid top-lin growth
balanc potenti bottom-lin risk notabl higher labor interest
cost equal weight forward price-to-earnings multipl base multipl forward
ev/ebitda multipl base multipl sum-of-part methodolog
use base valuat year arriv unchang price target
click full note
strong execut breast implant miradri
howev downgrad hold buy stock price
strong start receiv approv vesta facil
april launch rebrand breast implant report strong first quarter
miradri system ad addit combin equiti
debt financ may
although remain optimist long-term opportun valuat
significantli ahead peer averag stock price exceed
target result downgrad rate hold buy
remov price target
bottom line would recommend investor move sidelin
sinc stock exceed price target continu forecast
strong top-line growth compani driven relaunch breast implant
increas sale market support behind miradri system although
compani improv financi posit equiti rais gain
access addit debt financ issu share equiti
offer increas share count moreov expect compani
continu burn cash fast pace effort drive continu revenu growth
therefor view stock fairli valu current level believ would
prudent investor initi new posit stock time
strong start compani success execut key goal
strategi first half
breast product april receiv fda approv vesta
facil allow compani begin commerci breast implant
manufactur site control launch begun coupl
rebrand opu breast implant moreov offer
warranti product higher warranti offer two
major competitor also expect compani competit posit aid
result sientra studi show low ruptur capsular
contractur reoper rate rel peer overal breast product
segment also support strong perform biocorneum
scar manag product portfolio tissu expand
miradri segment miradri revenu outperform initi expect
sequenti growth believ new salesforc made
numer ex-zeltiq rep perform well earli stage
expans optimist growth potenti miradri accord
competitor dermira derm nr highest patient satisfact rate
hyperhidrosi treatment
financi posit may complet offer upsiz
initi includ full exercis underwrit option
believ net proce coupl access addit
debt financ made avail upon approv vesta facil
suffici fund compani growth strategi end
valuat share trade ev/revenu estim peer
averag although believ premium valuat justifi due
growth potenti breast implant sweat reduct market believ
stock fairli valu level
click full note
warrant extend runway al data evalu
brainstorm rais exercis warrant per share
share well issuanc new warrant exercis price
per share estim compani cash includ
remain cirm support studi nurown al given
support cirm expect oper expens remain
per quarter rang increas per quarter
trial move full enrol model alreadi factor dilut
chang price target
fund pivot data pipelin expans capit rais extend
runway like end pivot trial nurown
al compani also posit expand nurown addit
bcli confer call review right-to-tri access al essenti
focu ever view right-to-tri sign law
call includ particip mani caregiv
patient heartbreak realli bcli compani discuss plan
patient potenti abl access nurown new may
elig risk patient educ fund see bottom line
compani evalu best appropri way patient
option potenti access nurown stori review
edit biocenturi link
confer call review right-to-tri rtt compani priorit educ
public conduct lengthi note al patient matt bellina spoke
call ask veteran access fund mr bellina work right-to-tri
bill two year present bill sign law
patient testimoni made compel argument urgenc al
media pass stephen hawkin perhap greatest scientist mind sinc
einstein recent dwight clark tight end san francisco made
catch launch superbowl video link pass away
age al
final compani decis rtt expect announc within week
compani particip like restrict paramet inclusion/
exclus criteria view critic point make clear demand like
go overwhelm given number patients/caregiv heard
confer call said brainstorm evalu intern path forward
area brainstorm like focu rtt
patient/caregiv educ understand heterogen diseas access
expect given sever diseas understand differ
compassion use right-to-tri
build support/infrastructur potenti access compani plan
gather support kol principl investig regul
cost access nurown access rtt brainstorm intend
make access patient without mean pay therapi thu
wealthi brainstorm plan find financ assum foundat institut
grant etc support cost therapi
click full note
posit signific opportun exist acn
apr result rel in-line estim consensu
april cash cash equival
januari due primarili warrant exercis provid
compani
bpmx announc june regain complianc
nyse american continu list standard respect low stock
bottom line would continu buyer bpmx due larg address
market opportun two lead product candid expect bpmx sign
strateg partner fund acn trial end also look ahead
start phase rosacea studi bpmx submit protocol
fda moreov encourag compani improv cash posit
result warrant exercis provid addit runway compani fund
oper potenti clinic trial overal continu recommend bpmx
due belief topic minocyclin product could transform
treatment acn rosacea
apr result summari yesterday market close bpmx report
revenu y/i slightli estim
consensu import note bpmx revenu
gener sale violet over-the-count pill breast tender gross
profit y/i estim consensu
loss per share compar slightli
narrow estim in-line consensu non-gaap loss per
share compar also slightli narrow
estim in-line consensu april cash cash
equival compani outstand debt
phase acn trial bpmx estim phase studi
treatment acn enrol subject cost roughli expect
compani sign strateg partnership fund trial end
phase rosacea trial bpmx complet open-label studi
treatment rosacea submit protocol fda plan
dose vehicl expect trial cost
fund proce compani public offer close
warrant exercis yesterday press
releas bpmx indic phase rosacea program track
continu expect trial commenc third quarter calendar
product candid expect bpmx submit new product candid
fda next month
compel valuat deriv price target employ
dcf analysi discount rate perpetu growth rate
click full note
expand collabor helio indic
non-dilut capit posit
announc expand agreement helio kk nr
includ addit indic bring addit
capit associ deal dr hardi kagimoto ceo
helio nomin elect june board
director
agreement includ exclus licens commerci right
healio follow
japan multistem acut respiratori distress syndrom ard
multistem ipsc-deriv cell certain organ
certain ophthalmolog
indic
monotherapi combin retin pigment epitheli cell use
return receiv capit escrow anoth
four quarterli instal
runway includ escrow first
payment estim current cash balanc
sheet year runway current per quarter burn rate
expand deal also includ mileston develop
commerci well tier double-digit royalti
conclus expand collabor bring addit non-dilut
capit well expand opportun japan global japan
stroke trial on-going view focu initi
us stroke studi expand multistem pipelin program trauma
drive global stroke effort europe/fda japan decis
consist messag cell therapi safe burden
trial focus efficaci demonstr signific p-valu around primari
endpoint us/europ trial design almost ident japan except
primari endpoint us trial shift analysi secondari endpoint
excel outcom japan trial opposit japan treasur studi
continu enrol us studi plan initi quarter
us studi initi expand site europ
traumat injuri multistem- traumat injuri lead caus death
disabl among peopl age likewis stroke one lead
caus death disabl age multistem
potenti viabl therapeut two larg indic link two
immun dysfunct follow initi injuri stroke trauma treatment
patient experi sever trauma first treat er
surviv transfer icu recov recoveri process
hyperinflammatori respons result system inflammatori respons syndrom
essenti patient develop sever peripher hyperimmun respons
damag organ lead complic high rate mortal follow
hyperinflamm immun system sever deplet exhaust leav
patient suscept infect multistem neutral front back end blunt
hyper-inflamm protect immun deplet therebi promot
restor immun homeostasi induc better recoveri
click full note
mesoblast report march quarter fy june net loss
end period cash balanc sheet compani
credit facil drawn march
estim compani runway
prepar remestemcel-l fda submiss gvhd mesoblast
discuss fda regard upcom data trial
gvhd regulatori path forward base discuss
mesoblast believ day survival/safeti data combin
survival/safeti data could suffici file acceler
review us addit data end-stag heart failur
expect catalyst updat
mesoblast move car-t allogen announc mesoblast
enter partnership carther privat develop allogen car-
cell initi target ovarian gastric cancer car-t space
allogen treatment goal allow mass manufactur could
address issu face recent launch car-t logist challeng
all-in cost mesoblast bring experi manufactur
capabl allogen cell therapi space potenti emerg
signific player allogen car-t side view
conclus mesoblast multipl late stage clinic program data
readout next year provid catalyst stock
program heart failur gvhd lower back pain main focu
also highlight new car-t partnership yet factor
model
heart failur hf studi class ii-iii hf enrol
patient track complet enrol studi
end-stag hf class iv complet enrol data expect
smaller studi patient advanc diseas
posit signal efficaci could potenti read-through larger studi
view see data readout signific catalyst meso
graft vs host diseas remestemcel-l open-label data steroid-refractori
acut gvhd met endpoint overal respons rate orr increas
children treat remestemcel-l compar control
expect direct comparison open-label studi surviv data
day safeti data expect respect
chronic low back pain studi pain associ
degen disc diseas complet enrol march vs
initi target reach remain patient
screen process enrol trial endpoint demonstr improv
pain function month expect data prior studi
singl inject mpc spinal disc space result statist
signific improv pain function measur durabl month
rheumatoid arthriti ra data studi demonstr durabl
efficaci anti-tnf refractori patient go week total data
use design program
click full note
review triple-beat quarter increment sale
growth boost steep like follow
maintain buy rate price target coffe hold compani
jva follow releas april result earlier today
jva post all-around beat quarter ep vs
maxim along better-than-expect sale margin
expens relat jva acquisit comfort food behind
well given turnkey natur steep acquisit see
manag focu shift integr increment higher-margin
ep
gross margin actual vs maxim
oper margin actual vs maxim
manag provid guidanc financi metric
jva post all-around beat quarter ep vs maxim
along better-than-expect sale margin attribut jva bottom-
line beat higher-margin brand third-parti roast coffe sale replac
reduct wholesal green coffe sale keurig green mountain though jva
also report increas green coffe sale primari concern arabica
coffe price near low-end three-year rang exhibit may exert
modest margin pressur inventori though believ pressur
off-set strong sale higher-margin brand coffe
expens relat jva acquisit comfort food behind
well given turnkey natur steep acquisit see
manag focu shift integr increment higher-margin top-
line growth part y/i gain oper margin attribut
lap sg expens tie comfort food acquisit estim
remov integr cost alon add much
ep april compani report said recent acquisit
steep would accret sale margin day one thank
increment high-margin foodservic sale absenc increment sg
expens although model addit expens pre-tax
oper margin annual expand distribut expect
off-set higher margin foodservic channel provid well
potenti consolid roast facil jva exist brecksvil oh plant
also model ep upsid increment buyback estim buyback
jva repurchas program add least annual ep
anticip follow-up program expect strong free cash flow
ep estim forward ev/ebitda jva offer
compel upsid potenti view unchang price target jva
reflect primarili outlook acceler top-lin growth margin expans
stabl commod cost lower tax rate equal weight forward price-to-earnings multipl
base peer multipl forward ev/ebitda multipl base peer
multipl forward sale multipl base peer multipl methodolog
arriv price target
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
receiv full disclosur compani maxim group coverag mention report pleas send
